{"protocolSection": {"identificationModule": {"nctId": "NCT01902290", "orgStudyIdInfo": {"id": "20120141"}, "secondaryIdInfos": [{"id": "2012-003351-11", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility", "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility"}, "statusModule": {"statusVerifiedDate": "2022-09", "overallStatus": "TERMINATED", "whyStopped": "Study terminated early due to lack of efficacy observed following interim analysis in Q2 2015. Study Closed once all sites were closed in eClinical", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-05-22", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2015-05-15", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-05-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-05-22", "studyFirstSubmitQcDate": "2013-07-16", "studyFirstPostDateStruct": {"date": "2013-07-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-02-03", "resultsFirstSubmitQcDate": "2022-02-03", "resultsFirstPostDateStruct": {"date": "2022-02-28", "type": "ACTUAL"}, "dispFirstSubmitDate": "2016-03-14", "dispFirstSubmitQcDate": "2016-03-14", "dispFirstPostDateStruct": {"date": "2016-04-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-09-08", "lastUpdatePostDateStruct": {"date": "2022-09-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}, "collaborators": [{"name": "Kyowa Kirin Co., Ltd.", "class": "INDUSTRY"}, {"name": "AstraZeneca", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if brodalumab (AMG 827) is safe and effective compared to placebo as measured by change in Asthma Control Questionnaire (ACQ) composite scores."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Inadequately controlled asthma, brodalumab, AMG 827"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 421, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.", "interventionNames": ["Biological: Placebo"]}, {"label": "Brodalumab 210 mg", "type": "EXPERIMENTAL", "description": "Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.", "interventionNames": ["Biological: Brodalumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo administered subcutaneously", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Brodalumab", "description": "Brodalumab administered subcutaneously", "armGroupLabels": ["Brodalumab 210 mg"], "otherNames": ["AMG 827"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24", "description": "The ACQ is a validated instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nThe ACQ assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon wakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and FEV1. All seven items are scored on a 7-point scale, with 0 indicating good control and 6 indicating poor control; the total score is the mean of the seven items and ranges from 0 (totally-controlled) to 6 (extremely poorly controlled). A negative change from baseline indicates improvement. A change of 0.50 points is considered clinically meaningful and a total score of \\< 1.0 indicates good asthma control.", "timeFrame": "Baseline and week 24"}], "secondaryOutcomes": [{"measure": "Asthma Exacerbation Rate", "description": "The asthma exacerbation event rate is defined as the number of events per subject-year during the 24 week treatment period. An asthma exacerbation was defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study; distinct asthma exacerbations were defined as events with start dates more than 10 days apart from each other.", "timeFrame": "Baseline to week 24"}, {"measure": "Change From Baseline in ACQ Composite Score at Week 24 in ICS+LABA Subpopulation", "description": "The ACQ is a validated instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nThe ACQ assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon wakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and FEV1. All seven items are scored on a 7-point scale, with 0 indicating good control and 6 indicating poor control; the total score is the mean of the seven items and ranges from 0 (totally-controlled) to 6 (extremely poorly controlled). A negative change from baseline indicates improvement. A change of 0.50 points is considered clinically meaningful and a total score of \\< 1.0 indicates good asthma control.", "timeFrame": "Baseline and week 24"}, {"measure": "Asthma Exacerbation Rate in ICS+LABA Subpopulation", "description": "The asthma exacerbation event rate is defined as the number of events per subject-year during the 24 week treatment period. An asthma exacerbation was defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study; distinct asthma exacerbations were defined as events with start dates more than 10 days apart from each other.", "timeFrame": "Baseline to week 24"}, {"measure": "Change From Baseline in Daily Asthma Symptom Score (7-day Average Score)", "description": "The Asthma Symptom Diary (ASD) consists of 23 questions answered on a handheld device, including 10 asthma symptom-related items (5 answered in the morning and 5 in the evening).\n\nThe morning diary comprises questions on 4 asthma-related symptoms (wheezing, shortness of breath, cough, chest tightness), rated on a 5-point severity scale from 0 (no symptom) to 4 (very severe symptoms), and 1 question on nocturnal awakenings, rated from 0 (did not wake up) to 4 (unable to sleep due to asthma). The evening diary has questions on the same 4 asthma-related symptoms and 1 question on limitations of activities, rated from 0 (not at all) to 4 (extremely).\n\nThe ASD daily score is computed by averaging the responses to the 10 symptom-related items, and the mean 7-day ASD score is calculated by averaging the 7 daily scores, with the final score ranging from 0 (minimal symptoms) to 4 (very severe symptoms).", "timeFrame": "Baseline and week 24"}, {"measure": "Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)", "timeFrame": "Baseline and week 24"}, {"measure": "Change From Baseline in Daily Rescue Short-acting Beta-agonist Use", "description": "Participants were permitted allowed to use their inhaled rescue medication (SABA) as needed throughout the study and the use was captured in the daily electronic diary (eDiary).", "timeFrame": "Baseline and week 24"}, {"measure": "Time to First Asthma Exacerbation", "description": "An asthma exacerbation is defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study. Median time to first asthma exacerbation could not be estimated, the percentage of participants with an asthma exacerbation is reported.", "timeFrame": "From first dose of study drug to week 24"}, {"measure": "Number of Participants Who Experienced an Asthma Exacerbation", "description": "An asthma exacerbation is defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study.", "timeFrame": "Baseline to week 24"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score", "description": "The AQLQ is an asthma-specific instrument that includes evaluations of both symptoms and health-related quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms.\n\nParticipants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score was calculated as mean of the responses to the 32 questions and ranges from 1 (severe impairment) to 7 (no impairment). A positive change from baseline indicates improvement.", "timeFrame": "Baseline and week 24"}, {"measure": "Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEFR)", "description": "Peak expiratory flow rate was measured by the participant twice daily at approximately the same time each day (eg, within 1 hour of waking and immediately before bedtime) using a peak flow meter.", "timeFrame": "Baseline and week 24"}, {"measure": "Change From Baseline in Variation of Peak Flow", "description": "Peak flow was measured by the participant twice daily at approximately the same time each day (eg, within 1 hour of waking and immediately before bedtime) using a peak flow meter. The variation of peak flow is defined as the absolute value of the difference between the A.M. and P.M. peak flow in one day for an individual participant.", "timeFrame": "Baseline and week 24"}, {"measure": "Proportion of Asthma Symptom-free Days in 4-weeks Intervals Over the Treatment Period", "description": "Asthma symptom-free days is defined as days that a participant had a score of zero in their daily asthma symptom diary score.\n\nThe ASD consists of 23 questions answered on a handheld device, including 10 asthma symptom-related items (5 answered in the morning and 5 in the evening).\n\nThe morning diary comprises questions on 4 asthma-related symptoms (wheezing, shortness of breath, cough, chest tightness), rated on a 5-point severity scale from 0 (no symptom) to 4 (very severe symptoms), and 1 question on nocturnal awakenings, rated from 0 (did not wake up) to 4 (unable to sleep due to asthma). The evening diary has questions on the same 4 asthma-related symptoms and 1 question on limitations of activities, rated from 0 (not at all) to 4 (extremely).\n\nThe daily score is the average of the responses to the 10 items.", "timeFrame": "Baseline (the 4 weeks prior to first dose) and 4-week intervals up to week 24"}, {"measure": "Serum Brodalumab Concentration", "description": "Serum brodalumab concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) = 0.0500 \u00b5g/mL; values below the LLOQ were set to zero.", "timeFrame": "Day 1 and weeks 1, 2, 4, 8, 12, 16, and 22 at predose, week 2 + 3 days, week 22 + 3, 7, 10, and 14 days"}], "otherOutcomes": [{"measure": "Number of Participants With Treatment-emergent Adverse Events (TEAEs)", "description": "Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.\n\nThe investigator assessed whether the adverse event was possibly related to the investigational product.\n\nA serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria:\n\n* fatal;\n* life threatening;\n* requires in-patient hospitalization or prolongation of existing hospitalization;\n* results in persistent or significant disability/incapacity;\n* congenital anomaly/birth defect;\n* other medically important serious event.", "timeFrame": "From first dose of study drug up to the end of study, 28 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (FEV1) of \u2265 20% at screening\n* Percent of predicted FEV1 \u2265 40% and \u2264 80% at screening\n* Inhaled corticosteroid (ICS) \u2265 200 and \u2264 1000/\u03bcg/day fluticasone powder or equivalent\n* Ongoing asthma symptoms with asthma control questionnaire (ACQ) composite score at screening and baseline \u2265 1.5 points\n\nExclusion Criteria:\n\n* History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma\n* History of allergic bronchopulmonary aspergillosis\n* Respiratory infection within 4 weeks of screening or 1 week of baseline visit\n* Subject has known history of Crohn's disease\n* Subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol\n* Subject has previously used any anti-interleukin-17 (IL17) biologic therapy\n* Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study\n* Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile\n* Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)\n* Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Glendale", "state": "Arizona", "zip": "85306", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "zip": "85006", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Research Site", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Research Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "North Hollywood", "state": "California", "zip": "91606", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Research Site", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Research Site", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Research Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "San Diego", "state": "California", "zip": "92108", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Research Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Research Site", "city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Waterbury", "state": "Connecticut", "zip": "06708", "country": "United States", "geoPoint": {"lat": 41.55815, "lon": -73.0515}}, {"facility": "Research Site", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Jacksonville", "state": "Florida", "zip": "32256", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Research Site", "city": "Lynn Haven", "state": "Florida", "zip": "32444", "country": "United States", "geoPoint": {"lat": 30.24548, "lon": -85.64826}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32806", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Port Orange", "state": "Florida", "zip": "32127", "country": "United States", "geoPoint": {"lat": 29.13832, "lon": -80.99561}}, {"facility": "Research Site", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Research Site", "city": "Decatur", "state": "Georgia", "zip": "30033", "country": "United States", "geoPoint": {"lat": 33.77483, "lon": -84.29631}}, {"facility": "Research Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Research Site", "city": "Eagle", "state": "Idaho", "zip": "83616", "country": "United States", "geoPoint": {"lat": 43.69544, "lon": -116.35401}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60616", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Chicago", "state": "Illinois", "zip": "60637", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Research Site", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Research Site", "city": "Peoria", "state": "Illinois", "zip": "61603", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Research Site", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Research Site", "city": "Paducah", "state": "Kentucky", "zip": "42003", "country": "United States", "geoPoint": {"lat": 37.08339, "lon": -88.60005}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "zip": "21224", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Research Site", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Research Site", "city": "Plymouth", "state": "Minnesota", "zip": "55441", "country": "United States", "geoPoint": {"lat": 45.01052, "lon": -93.45551}}, {"facility": "Research Site", "city": "Jackson", "state": "Mississippi", "zip": "39216", "country": "United States", "geoPoint": {"lat": 32.29876, "lon": -90.18481}}, {"facility": "Research Site", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Research Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Research Site", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Research Site", "city": "Albuquerque", "state": "New Mexico", "zip": "87109", "country": "United States", "geoPoint": {"lat": 35.08449, "lon": -106.65114}}, {"facility": "Research Site", "city": "Rochester", "state": "New York", "zip": "14618", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Research Site", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Research Site", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Dublin", "state": "Ohio", "zip": "43016", "country": "United States", "geoPoint": {"lat": 40.09923, "lon": -83.11408}}, {"facility": "Research Site", "city": "Middleburg Heights", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "zip": "97202", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "zip": "19013", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "Rock Hill", "state": "South Carolina", "zip": "29732", "country": "United States", "geoPoint": {"lat": 34.92487, "lon": -81.02508}}, {"facility": "Research Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Research Site", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Research Site", "city": "Nashville", "state": "Tennessee", "zip": "37203-1424", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Research Site", "city": "Nashville", "state": "Tennessee", "zip": "37214", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "Research Site", "city": "Arlington", "state": "Texas", "zip": "76018", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78258", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Clinton", "state": "Utah", "zip": "84015", "country": "United States", "geoPoint": {"lat": 41.13967, "lon": -112.0505}}, {"facility": "Research Site", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "Research Site", "city": "Milwaukee", "state": "Wisconsin", "zip": "53226", "country": "United States", "geoPoint": {"lat": 43.0389, "lon": -87.90647}}, {"facility": "Research Site", "city": "New Lambton", "state": "New South Wales", "zip": "2305", "country": "Australia", "geoPoint": {"lat": -32.95, "lon": 151.68333}}, {"facility": "Research Site", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8H 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Kelowna", "state": "British Columbia", "zip": "V1W 1V3", "country": "Canada", "geoPoint": {"lat": 49.88307, "lon": -119.48568}}, {"facility": "Research Site", "city": "Surrey", "state": "British Columbia", "zip": "V3T 0G9", "country": "Canada", "geoPoint": {"lat": 49.10635, "lon": -122.82509}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V6J 1S3", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Brampton", "state": "Ontario", "zip": "L6T 0G1", "country": "Canada", "geoPoint": {"lat": 43.68341, "lon": -79.76633}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Newmarket", "state": "Ontario", "zip": "L3Y 5G8", "country": "Canada", "geoPoint": {"lat": 44.05011, "lon": -79.46631}}, {"facility": "Research Site", "city": "Sarnia", "state": "Ontario", "zip": "N7T 4X3", "country": "Canada", "geoPoint": {"lat": 42.97866, "lon": -82.40407}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Toronto", "state": "Ontario", "zip": "M9V 4B4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Research Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Le Kremlin Bicetre", "zip": "94270", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Research Site", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier cedex 05", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Pessac Cedex", "zip": "33604", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"facility": "Research Site", "city": "Saint Herblain", "zip": "44805", "country": "France", "geoPoint": {"lat": 47.21765, "lon": -1.64841}}, {"facility": "Research Site", "city": "Strasbourg cedex", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Tours Cedex 9", "zip": "37044", "country": "France", "geoPoint": {"lat": 47.38333, "lon": 0.68333}}, {"facility": "Research Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Berlin", "zip": "12099", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Bonn", "zip": "53119", "country": "Germany", "geoPoint": {"lat": 50.73438, "lon": 7.09549}}, {"facility": "Research Site", "city": "Cottbus", "zip": "03050", "country": "Germany", "geoPoint": {"lat": 51.75769, "lon": 14.32888}}, {"facility": "Research Site", "city": "Frankfurt am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "zip": "30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Radebeul", "zip": "01445", "country": "Germany", "geoPoint": {"lat": 51.10654, "lon": 13.66047}}, {"facility": "Research Site", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Research Site", "city": "Alexandroupoli", "zip": "68100", "country": "Greece", "geoPoint": {"lat": 40.84995, "lon": 25.87644}}, {"facility": "Research Site", "city": "Athens", "zip": "10676", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Research Site", "city": "Athens", "zip": "11527", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Research Site", "city": "Athens", "zip": "11528", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Research Site", "city": "Athens", "zip": "15125", "country": "Greece", "geoPoint": {"lat": 37.97945, "lon": 23.71622}}, {"facility": "Research Site", "city": "Chaidari, Athens", "zip": "12462", "country": "Greece"}, {"facility": "Research Site", "city": "Heraklion - Crete", "zip": "71110", "country": "Greece"}, {"facility": "Research Site", "city": "Thessaloniki", "zip": "57010", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Research Site", "city": "Hong Kong", "country": "Hong Kong", "geoPoint": {"lat": 22.27832, "lon": 114.17469}}, {"facility": "Research Site", "city": "New Territories", "country": "Hong Kong"}, {"facility": "Research Site", "city": "Cork", "country": "Ireland", "geoPoint": {"lat": 51.89797, "lon": -8.47061}}, {"facility": "Research Site", "city": "Dublin", "zip": "15", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Research Site", "city": "Dublin", "zip": "24", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Research Site", "city": "Dublin", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Research Site", "city": "Catania", "zip": "95123", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Research Site", "city": "Ferrara", "zip": "44121", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "Research Site", "city": "Genova", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Research Site", "city": "Modena", "zip": "41124", "country": "Italy", "geoPoint": {"lat": 44.64783, "lon": 10.92539}}, {"facility": "Research Site", "city": "Padova", "zip": "35128", "country": "Italy", "geoPoint": {"lat": 45.40797, "lon": 11.88586}}, {"facility": "Research Site", "city": "Pavia", "zip": "27100", "country": "Italy", "geoPoint": {"lat": 45.19205, "lon": 9.15917}}, {"facility": "Research Site", "city": "Pisa", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Research Site", "city": "Tradate (VA)", "zip": "21049", "country": "Italy"}, {"facility": "Research Site", "city": "Bucheon-si, Gyeonggi-do", "zip": "420-767", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Research Site", "city": "Seoul", "zip": "142-703", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Wonju-si, Gangwon-do", "zip": "220-710", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Christchurch", "zip": "8140", "country": "New Zealand", "geoPoint": {"lat": -43.53333, "lon": 172.63333}}, {"facility": "Research Site", "city": "Dunedin", "zip": "9058", "country": "New Zealand", "geoPoint": {"lat": -45.87416, "lon": 170.50361}}, {"facility": "Research Site", "city": "Remuera", "zip": "1051", "country": "New Zealand", "geoPoint": {"lat": -36.88041, "lon": 174.79819}}, {"facility": "Research Site", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Bialystok", "zip": "15-044", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Gdynia", "zip": "81-338", "country": "Poland", "geoPoint": {"lat": 54.51889, "lon": 18.53188}}, {"facility": "Research Site", "city": "Katowice", "zip": "40-954", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-011", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-024", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Krakow", "zip": "31-637", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lublin", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Skierniewice", "zip": "96-100", "country": "Poland", "geoPoint": {"lat": 51.95485, "lon": 20.15837}}, {"facility": "Research Site", "city": "Tarnow", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Warszawa", "zip": "01-868", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "02-097", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "02-201", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "04-141", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Zgierz", "zip": "95-100", "country": "Poland", "geoPoint": {"lat": 51.85561, "lon": 19.40623}}, {"facility": "Research Site", "city": "San Juan", "zip": "00917", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Research Site", "city": "Moscow", "zip": "105077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "115280", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "115446", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "119991", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Moscow", "zip": "127018", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Research Site", "city": "Saint Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Saint-Petersburg", "zip": "195271", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Taipei", "zip": "10002", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "22050", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}]}, "referencesModule": {"references": [{"pmid": "30945020", "type": "BACKGROUND", "citation": "Globe G, Wiklund I, Mattera M, Zhang H, Revicki DA. Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. J Patient Rep Outcomes. 2019 Apr 3;3(1):22. doi: 10.1186/s41687-019-0109-2."}], "seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants underwent 3 run-in visits over 4 weeks after completing screening assessments and meeting eligibility criteria. After the run-in visits, eligibility of asthma control questionnaire (ACQ), forced expiratory volume in 1 second (FEV1), and reversibility were confirmed. Eligible participants were randomized in a 1:1 ratio to 1 of 2 arms, stratified based on the current use of long acting \u03b2-agonist (LABAs) and number of prior exacerbations (\u2264 2 or \\> 2) in the past year before screening.", "recruitmentDetails": "This study was conducted at 157 centers in Asia, Australia, Canada, Europe, and the United States.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "FG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "210"}, {"groupId": "FG001", "numSubjects": "211"}]}, {"type": "Received Study Drug", "achievements": [{"groupId": "FG000", "numSubjects": "207"}, {"groupId": "FG001", "numSubjects": "208"}]}, {"type": "COMPLETED", "comment": "Completed end of study visit at week 28", "achievements": [{"groupId": "FG000", "numSubjects": "162"}, {"groupId": "FG001", "numSubjects": "158"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "53"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "27"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Sponsor Decision", "reasons": [{"groupId": "FG000", "numSubjects": "26"}, {"groupId": "FG001", "numSubjects": "24"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The full analysis set includes all participants who received at least 1 dose of study drug.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "BG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "207"}, {"groupId": "BG001", "value": "208"}, {"groupId": "BG002", "value": "415"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "47.3", "spread": "13.3"}, {"groupId": "BG001", "value": "47.2", "spread": "14.0"}, {"groupId": "BG002", "value": "47.3", "spread": "13.6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "120"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "242"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "86"}, {"groupId": "BG002", "value": "173"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "21"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "199"}, {"groupId": "BG001", "value": "195"}, {"groupId": "BG002", "value": "394"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "23"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "48"}]}, {"title": "Multiple", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "174"}, {"groupId": "BG002", "value": "336"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Randomization Strata", "description": "Data reported are corrected for errors entered into the Interactive Voice Response System (IVRS) at randomization.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "LABA -No; \u2264 2 asthma exacerbation prior year", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "37"}, {"groupId": "BG002", "value": "67"}]}, {"title": "LABA -No; > 2 asthma exacerbation prior year", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "LABA -Yes; \u2264 2 asthma exacerbation prior year", "measurements": [{"groupId": "BG000", "value": "160"}, {"groupId": "BG001", "value": "153"}, {"groupId": "BG002", "value": "313"}]}, {"title": "LABA -Yes; > 2 asthma exacerbation prior year", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "34"}]}]}]}, {"title": "Duration of Asthma", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22.20", "spread": "14.89"}, {"groupId": "BG001", "value": "22.92", "spread": "14.44"}, {"groupId": "BG002", "value": "22.56", "spread": "14.66"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24", "description": "The ACQ is a validated instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nThe ACQ assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon wakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and FEV1. All seven items are scored on a 7-point scale, with 0 indicating good control and 6 indicating poor control; the total score is the mean of the seven items and ranges from 0 (totally-controlled) to 6 (extremely poorly controlled). A negative change from baseline indicates improvement. A change of 0.50 points is considered clinically meaningful and a total score of \\< 1.0 indicates good asthma control.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.815", "spread": "0.073"}, {"groupId": "OG001", "value": "-0.865", "spread": "0.074"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.5219", "statisticalMethod": "Mixed-effect model", "statisticalComment": "The model included fixed effects of treatment group, time, interaction of treatment group by time, stratification variables, and baseline ACQ score.", "paramType": "Difference", "paramValue": "-0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.203", "ciUpperLimit": "0.103", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Asthma Exacerbation Rate", "description": "The asthma exacerbation event rate is defined as the number of events per subject-year during the 24 week treatment period. An asthma exacerbation was defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study; distinct asthma exacerbations were defined as events with start dates more than 10 days apart from each other.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "exacerbations per subject-year", "timeFrame": "Baseline to week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.57"}, {"groupId": "OG001", "value": "0.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.102", "statisticalMethod": "Generalized linear model", "statisticalComment": "Generalized linear model under a negative binomial distribution assumption adjusting for stratification factors.", "paramType": "Rate Ratio", "paramValue": "1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.93", "ciUpperLimit": "2.12", "estimateComment": "Rate ratio = Brodalumab : Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in ACQ Composite Score at Week 24 in ICS+LABA Subpopulation", "description": "The ACQ is a validated instrument used in clinical research and practice to evaluate asthma control/impairment.\n\nThe ACQ assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon wakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and FEV1. All seven items are scored on a 7-point scale, with 0 indicating good control and 6 indicating poor control; the total score is the mean of the seven items and ranges from 0 (totally-controlled) to 6 (extremely poorly controlled). A negative change from baseline indicates improvement. A change of 0.50 points is considered clinically meaningful and a total score of \\< 1.0 indicates good asthma control.", "populationDescription": "Full analysis set participants who were taking both inhaled corticosteroids (ICS) and a long-acting \u03b2-agonist (LABA) at baseline with available data.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.793", "spread": "0.084"}, {"groupId": "OG001", "value": "-0.831", "spread": "0.088"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6632", "statisticalMethod": "Mixed-effect model", "statisticalComment": "The model included fixed effects of treatment group, time, interaction of treatment group by time, stratification factors, and baseline ACQ score.", "paramType": "Difference", "paramValue": "-0.038", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.210", "ciUpperLimit": "0.134", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Asthma Exacerbation Rate in ICS+LABA Subpopulation", "description": "The asthma exacerbation event rate is defined as the number of events per subject-year during the 24 week treatment period. An asthma exacerbation was defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study; distinct asthma exacerbations were defined as events with start dates more than 10 days apart from each other.", "populationDescription": "Full analysis set participants taking both ICS and LABA at baseline with available data", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "exacerbations per subject-year", "timeFrame": "Baseline to week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.60"}, {"groupId": "OG001", "value": "0.89"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.096", "statisticalMethod": "Generalized linear model", "statisticalComment": "Generalized linear model under a negative binomial distribution assumption adjusting for stratification factors.", "paramType": "Rate Ratio", "paramValue": "1.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.94", "ciUpperLimit": "2.24", "estimateComment": "Rate ratio = Brodalumab : Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily Asthma Symptom Score (7-day Average Score)", "description": "The Asthma Symptom Diary (ASD) consists of 23 questions answered on a handheld device, including 10 asthma symptom-related items (5 answered in the morning and 5 in the evening).\n\nThe morning diary comprises questions on 4 asthma-related symptoms (wheezing, shortness of breath, cough, chest tightness), rated on a 5-point severity scale from 0 (no symptom) to 4 (very severe symptoms), and 1 question on nocturnal awakenings, rated from 0 (did not wake up) to 4 (unable to sleep due to asthma). The evening diary has questions on the same 4 asthma-related symptoms and 1 question on limitations of activities, rated from 0 (not at all) to 4 (extremely).\n\nThe ASD daily score is computed by averaging the responses to the 10 symptom-related items, and the mean 7-day ASD score is calculated by averaging the 7 daily scores, with the final score ranging from 0 (minimal symptoms) to 4 (very severe symptoms).", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "117"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.397", "spread": "0.042"}, {"groupId": "OG001", "value": "-0.443", "spread": "0.043"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3290", "statisticalMethod": "Mixed-effect model", "statisticalComment": "The model included fixed effects of treatment group, time, interaction of treatment group by time, stratification variables, and baseline score.", "paramType": "Difference", "paramValue": "-0.046", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.137", "ciUpperLimit": "0.046", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1)", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/s", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.207", "spread": "0.045"}, {"groupId": "OG001", "value": "0.237", "spread": "0.046"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4549", "statisticalMethod": "Mixed-effect model", "statisticalComment": "Model includes treatment, time, stratification factors, treatment by time and baseline value of age, gender, pooled race group, height and FEV1.", "paramType": "Difference", "paramValue": "0.030", "ciPctValue": "95", "ciLowerLimit": "-0.049", "ciUpperLimit": "0.109", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daily Rescue Short-acting Beta-agonist Use", "description": "Participants were permitted allowed to use their inhaled rescue medication (SABA) as needed throughout the study and the use was captured in the daily electronic diary (eDiary).", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "puffs", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "117"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.359", "spread": "0.243"}, {"groupId": "OG001", "value": "-1.231", "spread": "0.246"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.6317", "statisticalMethod": "Mixed-effect model", "statisticalComment": "The model included fixed effects of treatment group, time, interaction of treatment group by time, stratification variables, and baseline value.", "paramType": "Difference", "paramValue": "0.128", "ciPctValue": "95", "ciLowerLimit": "-0.396", "ciUpperLimit": "0.653", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation", "description": "An asthma exacerbation is defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study. Median time to first asthma exacerbation could not be estimated, the percentage of participants with an asthma exacerbation is reported.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "From first dose of study drug to week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.1"}, {"groupId": "OG001", "value": "23.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.238", "statisticalMethod": "Log Rank", "statisticalComment": "Log rank test stratified for baseline stratification factors.", "paramType": "Hazard Ratio (HR)", "paramValue": "1.277", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.843", "ciUpperLimit": "1.936"}]}, {"type": "SECONDARY", "title": "Number of Participants Who Experienced an Asthma Exacerbation", "description": "An asthma exacerbation is defined as an asthma worsening that requires systemic corticosteroids for at least 3 days during the study.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Baseline to week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.351", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Logistic regression adjusted for stratification factors.", "paramType": "Odds Ratio (OR)", "paramValue": "1.25", "ciPctValue": "95", "ciLowerLimit": "0.78", "ciUpperLimit": "2.01"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score", "description": "The AQLQ is an asthma-specific instrument that includes evaluations of both symptoms and health-related quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms.\n\nParticipants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score was calculated as mean of the responses to the 32 questions and ranges from 1 (severe impairment) to 7 (no impairment). A positive change from baseline indicates improvement.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "score on a scale", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.804", "spread": "0.085"}, {"groupId": "OG001", "value": "0.803", "spread": "0.087"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.9870", "statisticalMethod": "Mixed-effects model", "statisticalComment": "The model included fixed effects of treatment group, time, interaction of treatment group by time, stratification variables, and baseline AQLQ score.", "paramType": "Difference", "paramValue": "-0.001", "ciPctValue": "95", "ciLowerLimit": "-0.174", "ciUpperLimit": "0.171", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEFR)", "description": "Peak expiratory flow rate was measured by the participant twice daily at approximately the same time each day (eg, within 1 hour of waking and immediately before bedtime) using a peak flow meter.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"title": "Morning peak flow", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.072", "spread": "5.813"}, {"groupId": "OG001", "value": "0.706", "spread": "5.885"}]}]}, {"title": "Evening peak flow", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "135"}, {"groupId": "OG001", "value": "129"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-10.008", "spread": "5.719"}, {"groupId": "OG001", "value": "-4.089", "spread": "5.771"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis of morning peak flow", "nonInferiorityType": "SUPERIORITY", "pValue": "0.9053", "statisticalMethod": "Mixed-effect model", "statisticalComment": "Model includes treatment, time, stratification factors, treatment by time and baseline value of age, gender, pooled race group, height and AM PEFR.", "paramType": "Difference", "paramValue": "0.635", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.820", "ciUpperLimit": "11.089", "estimateComment": "Difference = Brodalumab - Placebo"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis of evening peak flow", "nonInferiorityType": "SUPERIORITY", "pValue": "0.2661", "statisticalMethod": "Mixed-effects model", "statisticalComment": "Model includes treatment, time, stratification factors, treatment by time and baseline value of age, gender, pooled race group, height and PM PEFR.", "paramType": "Difference", "paramValue": "5.920", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.515", "ciUpperLimit": "16.354", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Variation of Peak Flow", "description": "Peak flow was measured by the participant twice daily at approximately the same time each day (eg, within 1 hour of waking and immediately before bedtime) using a peak flow meter. The variation of peak flow is defined as the absolute value of the difference between the A.M. and P.M. peak flow in one day for an individual participant.", "populationDescription": "Full analysis set with available data", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L/min", "timeFrame": "Baseline and week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "121"}, {"groupId": "OG001", "value": "115"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.872", "spread": "2.135"}, {"groupId": "OG001", "value": "-4.892", "spread": "2.169"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0871", "statisticalMethod": "Mixed-effect model", "statisticalComment": "Model includes treatment, time, stratification factors, treatment by time and baseline value of age, gender, race group, height and PEFR variation.", "paramType": "Difference", "paramValue": "-4.021", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.627", "ciUpperLimit": "0.586", "estimateComment": "Difference = Brodalumab - Placebo"}]}, {"type": "SECONDARY", "title": "Proportion of Asthma Symptom-free Days in 4-weeks Intervals Over the Treatment Period", "description": "Asthma symptom-free days is defined as days that a participant had a score of zero in their daily asthma symptom diary score.\n\nThe ASD consists of 23 questions answered on a handheld device, including 10 asthma symptom-related items (5 answered in the morning and 5 in the evening).\n\nThe morning diary comprises questions on 4 asthma-related symptoms (wheezing, shortness of breath, cough, chest tightness), rated on a 5-point severity scale from 0 (no symptom) to 4 (very severe symptoms), and 1 question on nocturnal awakenings, rated from 0 (did not wake up) to 4 (unable to sleep due to asthma). The evening diary has questions on the same 4 asthma-related symptoms and 1 question on limitations of activities, rated from 0 (not at all) to 4 (extremely).\n\nThe daily score is the average of the responses to the 10 items.", "populationDescription": "Full analysis set with available data during each 4-week interval", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "proportion of days", "timeFrame": "Baseline (the 4 weeks prior to first dose) and 4-week intervals up to week 24", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "203"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.071", "spread": "0.179"}, {"groupId": "OG001", "value": "0.041", "spread": "0.125"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "204"}, {"groupId": "OG001", "value": "203"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.122", "spread": "0.239"}, {"groupId": "OG001", "value": "0.083", "spread": "0.195"}]}]}, {"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "193"}, {"groupId": "OG001", "value": "192"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.174", "spread": "0.302"}, {"groupId": "OG001", "value": "0.132", "spread": "0.268"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "185"}, {"groupId": "OG001", "value": "184"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.191", "spread": "0.319"}, {"groupId": "OG001", "value": "0.164", "spread": "0.298"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "176"}, {"groupId": "OG001", "value": "174"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.211", "spread": "0.328"}, {"groupId": "OG001", "value": "0.194", "spread": "0.335"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "162"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.222", "spread": "0.346"}, {"groupId": "OG001", "value": "0.203", "spread": "0.339"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "153"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.237", "spread": "0.371"}, {"groupId": "OG001", "value": "0.204", "spread": "0.342"}]}]}]}, {"type": "SECONDARY", "title": "Serum Brodalumab Concentration", "description": "Serum brodalumab concentrations were measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) = 0.0500 \u00b5g/mL; values below the LLOQ were set to zero.", "populationDescription": "Participants who received brodalumab with available concentration data at each time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "Day 1 and weeks 1, 2, 4, 8, 12, 16, and 22 at predose, week 2 + 3 days, week 22 + 3, 7, 10, and 14 days", "groups": [{"id": "OG000", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "196"}]}], "classes": [{"title": "Day 1 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "196"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "0"}]}]}, {"title": "Week 1 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "196"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.48", "spread": "5.55"}]}]}, {"title": "Week 2 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16.8", "spread": "9.85"}]}]}, {"title": "Week 2 day 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24.9", "spread": "15.8"}]}]}, {"title": "Week 4 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.5", "spread": "9.28"}]}]}, {"title": "Week 8 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11.1", "spread": "9.03"}]}]}, {"title": "Week 12 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "161"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.6", "spread": "9.86"}]}]}, {"title": "Week 16 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "150"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.93", "spread": "9.06"}]}]}, {"title": "Week 22 predose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.94", "spread": "9.32"}]}]}, {"title": "Week 22 day 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.0", "spread": "15.4"}]}]}, {"title": "Week 22 day 7", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "14.8", "spread": "13.3"}]}]}, {"title": "Week 22 day 10", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.5", "spread": "12.2"}]}]}, {"title": "Week 22 day 14", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "146"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.06", "spread": "9.78"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Number of Participants With Treatment-emergent Adverse Events (TEAEs)", "description": "Adverse events were graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.\n\nThe investigator assessed whether the adverse event was possibly related to the investigational product.\n\nA serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria:\n\n* fatal;\n* life threatening;\n* requires in-patient hospitalization or prolongation of existing hospitalization;\n* results in persistent or significant disability/incapacity;\n* congenital anomaly/birth defect;\n* other medically important serious event.", "populationDescription": "Randomized participants who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From first dose of study drug up to the end of study, 28 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}, {"id": "OG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "207"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"title": "Any treatment-emergent adverse event", "categories": [{"measurements": [{"groupId": "OG000", "value": "134"}, {"groupId": "OG001", "value": "156"}]}]}, {"title": "TEAE \u2265 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "Serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "TEAE leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Life-threatening adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Fatal adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-related treatment-emergent adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "44"}]}]}, {"title": "Treatment-related TEAE \u2265 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "14"}]}]}, {"title": "Treatment-related serious adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment-related TEAE leading to discontinuation of study drug", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Treatment-related life-threatening adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Treatment related fatal adverse events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "From first dose of study drug until the end of study, week 28.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo subcutaneous injections on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22.", "seriousNumAffected": 8, "seriousNumAtRisk": 207, "otherNumAffected": 104, "otherNumAtRisk": 207}, {"id": "EG001", "title": "Brodalumab 210 mg", "description": "Participants received brodalumab 210 mg administered by subcutaneous injection on day 1 and weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22.", "seriousNumAffected": 7, "seriousNumAtRisk": 208, "otherNumAffected": 129, "otherNumAtRisk": 208}], "seriousEvents": [{"term": "Microcytic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Bile duct adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Suicidal behaviour", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 208}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 208}]}], "otherEvents": [{"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 208}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 208}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 208}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 208}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 208}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 208}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 208}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 208}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 208}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 208}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 208}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 208}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 63, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 72, "numAtRisk": 208}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 208}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 208}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 208}]}, {"term": "Wheezing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 207}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 208}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."}, "pointOfContact": {"title": "Study Director", "organization": "Amgen Inc.", "email": "medinfo@amgen.com", "phone": "866-572-6436"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571216", "term": "Brodalumab"}], "ancestors": [{"id": "D000003879", "term": "Dermatologic Agents"}], "browseLeaves": [{"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M279808", "name": "Brodalumab", "asFound": "Chicken", "relevance": "HIGH"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}]}}, "hasResults": true}